Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19743392 | 0.82 | GAA (0.37) | MAPTGAALMNAHPGDALDH1A1 | |
| SCHEMBL30461818 | 0.82 | GAA (0.37) | MAPTGAALMNAHPGDALDH1A1 | |
| SCHEMBL30570049 | 0.81 | ALDH1A1 (0.40) | MAPTLMNAALDH1A1TERTHTR6 | |
| SCHEMBL3249990 | 0.81 | ALDH1A1 (0.40) | MAPTLMNAALDH1A1TERTHTR6 | |
| SCHEMBL11985888 | 0.75 | NQO2 (0.35) | MAPTLMNAHPGDALDH1A1NQO2 | |
| SCHEMBL25879715 | 0.74 | NOS2 (0.47) | MAPTGAALMNAHPGDALDH1A1 | |
| SCHEMBL25239817 | 0.73 | MBOAT4 (0.37) | MAPTGAAALDH1A1APOBEC3GHTT | |
| SCHEMBL30054247 | 0.73 | HSP90AA1 (0.48) | MAPTGAAHPGDALDH1A1CA2 | |
| SCHEMBL30478351 | 0.73 | MBOAT4 (0.37) | MAPTGAAALDH1A1APOBEC3GHTT | |
| SCHEMBL29127438 | 0.73 | SMN1; SMN2 (0.38) | MAPTGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447475-A | Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors | H.隆德贝克有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| CN-111511742-B | Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111556871-B | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-111491936-B | Macrocyclic compounds as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11535611-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-12-27 | — | — | US | disclosed |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-11-08 | — | — | US | disclosed |
| CN-111465410-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-111526890-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-14 | — | — | CN | disclosed |
| WO-2019115567-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H. LUNDBECK A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115566-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H. LUNDBECK A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| EP-3478681-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2019-05-08 | — | — | EP | disclosed |
| US-20190105302-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-04-11 | — | — | US | disclosed |
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| WO-2018007249-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-01-11 | — | — | WO | disclosed |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | MAPT 246/4885GAA 322/4885LMNA 2936/4885 |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | PDE3B, PDE1B, PDE12 | MAPT 80/4885GAA 334/4885LMNA 2745/4885 |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | MAPT 256/4885GAA 331/4885LMNA 2982/4885 |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | PDE1B, PDE3B, PDE1A | MAPT 749/4885GAA 702/4885LMNA 3970/4885 |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | PDE3A, PDE5A, PDE12 | MAPT 246/4885GAA 322/4885LMNA 2936/4885 |
| US-11535611-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | PDE5A, PDE12, PDE3A | MAPT 553/4885GAA 379/4885LMNA 3811/4885 |
| US-20190105302-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | PDE3A, PDE5A, PDE12 | MAPT 246/4885GAA 322/4885LMNA 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.